A study of ParvOryx in combination with Avastin(R) or with Avastin(R) plus an immune checkpoint inhibitor in a controlled clinical trial setting

Trial Profile

A study of ParvOryx in combination with Avastin(R) or with Avastin(R) plus an immune checkpoint inhibitor in a controlled clinical trial setting

Planning
Phase of Trial: Phase II

Latest Information Update: 31 May 2017

At a glance

  • Drugs H 1PV (Primary) ; Bevacizumab
  • Indications Glioblastoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2017 New trial record
    • 23 May 2017 According to an Oryx GmbH & Co media release, data from compassionate use programs is used to plan this trial. This trial will be discussed with regulatory authorities.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top